Tuesday, 14 November 2017

Press Release - BioLargo sets new sales records and continues to break through commercial barriers

Westminster, CA (November 14, 2017) – BioLargo, Inc., (OTCQB: BLGO; www.biolargo.com), a sustainable science, technology and full-service environmental engineering company that delivers practical solutions for clean water, clean air and advanced wound care, announced today the achievement of a series of noteworthy milestones, as reported in its quarterly report (click here) filed with the Securities and Exchange Commission. Highlights include:
CupriDyne Clean Industrial Odor Control
    • The company is actively servicing “national purchasing agreements” with three leaders in the solid waste handling industry, and product sales are increasing.
    • In 2017, product sales have increased each quarter – from approximately $50,000 in the first quarter, to almost $100,000 in the second, and $170,000 in this last quarter, representing approximately a 100% increase from Q1 to Q2, and a 70% increase in sales from Q2 to Q3.
    • The company is actively engaged in multiple odor-control trials in the wastewater treatment industry and is enjoying early success with municipal clients.
    • More than just delivering products, the company is working directly with clients to evaluate and assist in the use and design of various delivery methods and systems to help solve odor related problems.
    • The addition of the company’s in-house engineering team is allowing us to expand our capabilities and open new opportunities with existing and new clients.
    • On September 27, 2017, Clyra submitted an application for premarket notification under Section 510(k) for a wound care product. It is now in the formal 90-day review process by the FDA which is expected to conclude before years end. (Correction: the actual response may occur just after years end) 
    • Clyra closed a private securities offering of its common shares and accepted $1,000,000 in subscriptions, of which BioLargo invested $250,000 into Clyra.
    • Clyra’s management is actively engaged in arranging for clinical work and is in discussions with a number of potential strategic partners.
    • In September 2017, the company commenced a full service in-house environmental engineering firm and formed a wholly owned subsidiary named BioLargo Engineering, Science & Technologies, LLC.
    • The company’s first client is a CB&I spin off that provides engineering services worldwide, and they have already started providing services to local utilities.
    • BLEST is active evaluating, bidding on, negotiating, and generally pursing other substantial commercial opportunities.
    • Our AOS (Advanced Oxidation System) and our R & D team has been awarded more than 50 research grants from various Canadian public and private agencies, including the Canadian National Research Council – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC).
    • Through a project funded by a grant from the Metropolitan Water District of Southern California pursuant to its Innovative Conservation Program, we confirmed the technical capabilities of our AOS system to disinfect and decontaminate poultry, dairy and municipal tertiary effluent wastewater. The company’s next step is to engineer a higher volume and robust system for use in an onsite commercial pilot. Work is underway.
Company Highlights
    • To help provide growth capital to the Company, BioLargo has entered into a purchase agreement for up to $10 million of equity capital, subject to certain terms and conditions. (See Form 8-K here).  
    • All but $50,000 of the company’s $6.3 million debt obligations are convertible into common stock.
    • The company was awarded “Best Horizontal Disruption” High Tech Innovation Award by OCTANe (Orange County’s technology and life sciences accelerator organization) at its 24th annual award ceremony. (OCTANe press release here.)
    • The company’s team members were also honored presenters and award winners at multiple industry related conferences including the Metropolitan Water District of Southern California’s Agriculture and Industry Relations Committee meeting, Bluetech Week in San Diego sponsored by The Maritime Alliance, an international trade mission hosted by the Canadian Embassy and Consulate in Beijing and Guangzhou that was sponsored by NRC-IRAP (National Research Council of Canada), the Uptick Newswire “Uppie Award” for the “Most Promising Technology Growth” for 2017 and our CEO “Best CEO of the Year.” The company was also honored to be the Title Sponsor along with Metropolitan Water District of Southern California at Sustain OC’s recent Water Solutions 2 conference held at UC Irvine’s Applied Innovation Center in Irvine, California. 

Dennis P. Calvert, President and CEO of BioLargo commented, “We are enjoying the flywheel effect and its momentum is powerful. We are often reminded that our continued focus on our worthy mission to Make Life Better through innovation as well as our continued ability to attract exceptionally qualified talent and the continued support of our investors and public funding sources are all critical components to our continued success.  Technologies like ours can be a catalyst for change for good and we are a living testimony to the power of innovation combined with purpose for the greater good. In many ways we are just getting started and we can’t wait for tomorrow. I encourage our stakeholders to read the entire quarterly report for a complete understanding of the highlights listed in this press release.”

About BioLargo, Inc.
BioLargo, Inc. is a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air and advanced wound care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com) features an exceptional team of experienced specialists dedicated to integrity, reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous contaminants in water in a fraction of the time and cost of current technologies. Its odor division features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that that contends with malodors, VOC’s or similar air quality related problems. Its personal care product division features products in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). Its medical division (www.ClyraMedical.com) focuses on advanced wound care management, featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control and regenerative tissue therapy. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc (www.ClarionWater.com).   

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2


Friday, 10 November 2017

BioLargo Water Joins Canadian Trade Mission in China

BioLargo is on the road this week – in a big way. BioLargo, Inc. Director of Business Development Dr. Shan Yong is representing the company on a waste water-focused trade mission in China, funded by NRC-IRAP (National Research Council of Canada). In China, Dr. Yong is promoting BioLargo’s business development interests by seeking piloting opportunities for the company’s disruptive water treatment platform, the Advanced Oxidation System (AOS). She is also advancing discussions for the distribution of BioLargo’s CupriDyne Clean Industrial Odor Eliminator in Chinese markets, which follows the product’s explosive spread across the solid waste handling industry in the US.
Along with 7 other companies, BioLargo was selected by NRC-IRAP for this trade mission from more than 80 companies to explore collaborations with Chinese environment-focused companies and government agencies.












The trade mission is hosted by the Canadian Embassy and Consulate in Beijing and Guangzhou, and Dr. Yong is traveling with other innovative technology companies from Canada, including BQE Water, Protectolite, etc. They have traveled from Beijing to Guangzhou on a 5-day trip and have presented to numerous groups and participated in countless B2B meetings.

BioLargo President and CEO Dennis Calvert commented, “We are privileged to work beside the Canadian IRAP group with our Canadian water company. We believe this trip comes at a perfect time given our recent developmental proof-of-claim results for our AOS and commercial successes of our CupriDyne Clean odor control product. We are also proud to have our commercial opportunities pursued by our talented Dr. Shan Yong in Canada, the US, and in China.”


Monday, 6 November 2017

BioLargo named "Most Promising Technology Growth" for 2017 & CEO honored by Uptick Newswire


On Friday, November 3rd, BioLargo was honored by Uptick Newswire with the award for "Most Promising Technology Growth" for 2017, and the company's CEO, Dennis P. Calvert was named "Best CEO of the Year." We are very happy to receive these accolades in recognition of our hard work in the development of our disruptive technologies, and we are pleased that the ingenuity and leadership of our CEO have not gone unnoticed. 

Uptick Newswire and over 90+ CEOs joined together on November 3rd for Uptick's first annual "Uppie Awards". There were over 50 award nominees, and only 15 awards were presented at the event. 



Uptick Newswire is a top Micro-Cap news source in America. Its mission is to provide transparency to publicly traded companies and its Newsroom allows investors to research and find new companies for their portfolios. Uptick Newswire has cultivated a unique user base of investors, consumers and brokerage houses that receive information about penny-stock and OTC companies. Their objective is to build relationships between Micro-Cap companies and investors.


Dennis P. Calvert, BioLargo CEO commented, "We are honored to be recognized by Uptick and their exceptional team. The event showcased a number of quality companies and business leaders. We are thankful to work with Uptick and we have enjoyed our relationship over the past couple of years and look forward to many more.  As for these awards, the compliment really belongs to our exceptional team at BioLargo as we execute on our mission to "Make Life Better".  Remember, building a successful innovation company is a team sport!" 














Monday, 30 October 2017

Presentation at MWD of Southern California: "Highlights of BioLargo’s Innovation Journey: The Critical Role of Incubators and Accelerators"

BioLargo, Inc. President and CEO Dennis Calvert was honored last week to present at the Metropolitan Water District (MWD) of Southern California's Agriculture and Industry Relations Committee meeting, where he shared BioLargo's story of collaborating with incubators, accelerators, and academic researchers to achieve its breakthrough results for its AOS technology.

Dennis was honored to share a glimpse of  BioLargo's story to industry thought-leaders at MWD. See for yourself - you can watch Dennis' full presentation here, or follow the link below to view it on MWD's archives!

The first presenter was Wiggs Mendoza, an innovation specialist at MWD who provided an overview of the role of incubators and accelerators for the water industry.

Carlos Gutierrez from Larta Institute spoke at length about their strategy to support innovation and how they do it.  http://www.larta.org

Then Dennis was able to share a glimpse of BioLargo's innovation journey and acknowledge the critical role of its incubators and accelerators like MWD. He is introduced by Vice-Chairman Larry Dick of MWD.


You can also watch the full meeting at the link below, which includes the presentations of Wiggs Mendoza and Carlos Gutierrez!

http://mwdh2o.granicus.com/MediaPlayer.php?view_id=12&clip_id=6375&meta_id=157036

Wednesday, 18 October 2017

BioLargo's Clyra Medical Division 510(k) Application with FDA Offers New Technology for Advanced Wound Care - Tamarack Article

Article By: Tamarack Advisors. 
For a direct link to the article by Tamarack Advisors-
Go to the Accesswire link here!

The need for effective wound care products has never been greater. Growing global population, rapidly increasing antimicrobial resistance, and the diabetes epidemic among other things, are making it difficult for healthcare providers to effectively treat wounds, putting a strain on patients and also on healthcare systems. Medical professionals are constantly on the lookout for new and innovative methods to help heal difficult-to-treat or chronic wounds, resulting in an $18B market for advanced wound care products.










One such solution is poised to be offered by BioLargo, Inc. (OTC: BLGO) subsidiary, Clyra Medical Technologies. On September 22nd, BioLargo, Inc. (OTC: BLGO)  announced that Clyra submitted an FDA 510(k) application for an advanced wound care product. Clyra has developed a wound care formulation that integrates the well-understood staple of antimicrobial iodine into a revolutionary new product that is more effective yet gentler than current solutions. Additionally, Clyra’s product produces no known antimicrobial resistance and has shown sustained antimicrobial power for up to 3 days.

Iodine has been the considered a gold standard antimicrobial for nearly two hundred years. However, traditional iodine products contain high, toxic levels of iodine, which can be damaging to fibroblasts and delay wound healing. Consequently, physicians consider traditional iodine products as a “last resort,” preferring gentler antimicrobial treatments for managing chronic wounds, such as silver, honey, and hypochlorous acid. While these antimicrobials have various proven levels of efficacy, in each case they present some sort of tradeoff in practical use, such as high costs, potential for acquired resistance, cytotoxic implications (damage to skin or other cells), and a limited effective duration.   

A wound care antimicrobial formulated with high efficacy and without the tradeoffs of the most-often prescribed products on the market would be poised to disrupt the advanced wound care industry. That’s exactly what BioLargo’s Clyra Medical Technologies has done. Their product is broad-spectrum, highly effective, and doesn’t have the collateral tissue damage problems of previous iodine-based wound care products. It remains effective longer than traditional antimicrobials, has no-know microbial resistance, and with such a low level of iodine can be offered at lower costs. The Clyra product creates a wound environment that is much more amenable to healing and regeneration. Consequently, Clyra’s wound care product has the potential to provide immense benefit in innumerable chronic or difficult-to-treat wound situations, and Clyra anticipates having a big impact on the very competitive $18B advanced wound care market.

Clyra management reports that after years of development work, they have developed a proprietary technology that retains the full power of iodine, yet minimizes skin tissue damage so that the products can remain non-cytotoxic. While Clyra’s products will likely feature additional technical claims, features and benefits, its broad spectrum and sustained antimicrobial performance (including biofilm), coupled with its safety profile and low cost, distinguish it from alternative products.

In June, Clyra presented their breakthrough technology at the 15th annual Peter Sheehan Wound Healing: Science & Industry Conference in Puerto Rico, attended by leading wound care clinicians and researchers. We had a chance to speak with Clyra Medical President, Steve Harrison, about the new technology. He commented, "We are highly encouraged by the overwhelming positive response from the clinical wound care experts attending the conference. The data from the FDA pre-submission testing generated a great deal of enthusiasm among the leading clinicians and researchers at the conference.”

The presentation at the conference highlighted Clyra's advantages over existing wound care products:
  • Clyra's hydrogel wound dressings are highly effective and have no known microbial resistance.
  • GLP lab studies demonstrated sustained release and continued antimicrobial effectiveness against major organisms.
  • In vivo pig studies have shown effectiveness against mature biofilm, with better results than certain prescription antimicrobial solutions.
  • Non-cytotoxic, non-sensitizing, and safe to human cells.
  • Can easily integrate Clyra technologies into existing products and new ones in the pipeline, including regenerative tissue.

Dr. Brock Liden, DPM, a wound care expert with an extensive wound and limb salvage practice in Ohio, presented the latest Clyra data to the conference. He commented, "When I was introduced to the Clyra technology, I was very interested to learn more. This is a complex that has been shown to impact bacteria, and shows sustained activity, yet be safe to cells and the wound healing process. It may have clinical application to be used with cellular tissue products, stem cells, and growth factors with no harm to the modality. This is a significant breakthrough in the wound space. With further clinical research we may even have a modality to impact established biofilms while doing no harm to the host or the healing modalities being utilized. As I learn more about Clyra's technology, I feel that it has the potential to have a significant impact in wound care, as well as potential in other areas of medicine."

Mr. Harrison continued, “In keeping with BioLargo’s mission, our advanced wound care products have an important contribution to Make Life Better as we compete for a segment of the $18 billion global advanced wound care market. Our products are safe, gentle, and effective, and as such, we believe their role in infection control, chronic wound management and regenerative skin therapy are important and valuable. We are targeting early 2018 to be ready for market.”
Clyra is keenly aware of the competition they will face in the wound care industry.  One established competitor offering a broad line of antimicrobial wound care products including silver and iodine based offerings is Smith & Nephew (NYSE: SNN). Another competitor is Derma Sciences (honey), now owned by Integra LifeSciences Holdings Company (NASDAQ: IART). Senior Strategy Advisor to Clyra Medical, Tanya Rhodes, Ph.D., was the former Smith & Nephew Vice President of Innovation and Vice President at Smith & Nephew Wound Management. Dr. Rhodes invested 15 years at Smith & Nephew U.S., and more than 20 years in the wound management and skin care industry globally. She has established a broad base of expertise that includes a concept-to-commercialization philosophy utilizing product design, strategic marketing and evidence-based trials as well as reimbursement and regulatory compliance strategies. Over her career, she played an instrumental role in bringing a number of staple wound care technologies to market around the globe.
Management tells us that several additional products are in the pipeline and expected to follow.  Clyra’s wound care products’ data will also be presented at the upcoming SAWC (Symposium on Advanced Wound Care) fall meeting held in Las Vegas on October 20-22, 2017.
















About BioLargo, Inc.
BioLargo, Inc. is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.
Legal Disclaimer:


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

Tuesday, 17 October 2017

BioLargo Wins OCTANe OC High Tech Innovation Award!

We announced earlier this year that we were made a finalist for an industry innovation award given by Orange County's premier tech incubator, OCTANe - today we are happy to confirm that BioLargo won a High Tech Innovation award in the category of "Best: Horizontal Disruption"! This is a great honor for our company, and we think it heralds significant growth and adoption of our various innovative technology platforms: our AOS water treatment system, CupriDyne Clean Industrial Odor Eliminator, Clyra Medical Technologies, and the iSAN iodine dosing system.








To learn more about this award, read our press release here! This was the 24th annual OCTANe High Tech Innovation award program, and we are proud to have received this honor.

The award recognizes BioLargo's strength in developing disruptive technology solutions for a wide range of high-growth markets simultaneously. The term "horizontal disruption" denotes a business strategy where a company expands the use of an innovative, disruptive technology to affect (and displace) multiple non-overlapping markets or revenue streams - as opposed to vertical disruption, where a technology is leveraged to own a greater share of a single "vertical" value chain in one market. You can learn more about these concepts here and here!

Some of the other winners of this year's High Tech Innovation Awards included some big names in Southern Californian tech innovation, including HyperX, a juggernaut in computer components and video gaming peripherals.

  • HyperX
  • Alteryx
  • Arbitech
  • MeU CARE
  • CiE Digital Labs
  • Sonendo
  • IN CIRCL
  • Swift Engineering
  • Vertos Medical
  • Birch Street Systems

Friday, 29 September 2017

BioLargo’s Medical Subsidiary Files 510(k) with FDA for its Novel Wound Care Technology

Westminster, CA (Uptick Newswire – September 28, 2017) – BioLargo, Inc. (OTCQB:BLGO), a sustainable science and technology company that delivers practical solutions for clean water, clean air, and advanced wound care, announced today its subsidiary Clyra Medical Technologies had submitted to the Food & Drug Administration an application for premarket notification under Section 510(k) of the Food, Drug, and Cosmetic Act. By statute, Clyra must wait 90 days prior to going to market while the FDA evaluates the submission and determines whether to grant it clearance.







BioLargo also announced that the new technology and related data will be exhibited at the Symposium on Advanced Wound Care/Fall (SAWC/Fall), October 20 – 22, 2017, in Las Vegas, Nevada (http://www.sawc.net/fall/). The semi-annual SAWC meeting is the premier interdisciplinary wound care program and the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, researchers, and scientists are expected to attend the 2017 SAWC/Fall meeting.
Clyra Medical President Steve Harrison commented, “In keeping with BioLargo’s mission, our advanced wound care products have an important contribution to Make Life Better for those suffering with a wide variety of wounds. Our products are safe, gentle and effective, and as such, we believe their role in infection control, chronic wound management, and regenerative skin therapy are important and valuable. We hope this FDA submission is the first of many that will allow us to bring Clyra products to the Advanced Wound Care market.”
President & CEO of BioLargo, Dennis P. Calvert commented, “This very important milestone is another example of our dedication to build value for our shareholders. This project has required an army of supporters, investors, and a highly qualified technical team to make our vision for these products a reality. Through Clyra Medical we will serve others in a very high value market and we believe these platform products will play an important role in health care for decades to come.”
About BioLargo, Inc.
BioLargo, Inc. is a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air and advanced wound care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com) features an exceptional team of experienced specialists dedicated to integrity, reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous contaminants in water in a fraction of the time and cost of current technologies. Its odor division features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that that contends with malodors, VOC’s or similar air quality related problems. Its personal care product division features products in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). Its medical division (www.ClyraMedical.com) focuses on advanced wound care management, featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control and regenerative tissue therapy. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc (www.ClarionWater.com).                    
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2
Source: Uptick Newswire

widget